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IV. General Summary 
In comparison to apoptosis, programmed necrosis or necroptosis is a 
caspase-independent form of programmed cell death with proinflammatory 
properties due to uncontrolled release of intracellular contents upon 
membrane rupture and the concomitant secretion of danger associated 
molecular patterns (DAMPs) and proinflammatory cytokines. Programmed 
cell death is a crucial process involved in development and tissue 
homeostasis of organisms. The ability to induce programmed cell death is 
often disrupted in cancer cells and reveals an important strategy by which 
neoplastic cells promote survival and proliferation, as well as instead 
contributes to chemoresistance of cancer cells. 
Inhibitor of apoptosis proteins (IAPs) and receptor interacting protein kinases 
(RIPKs) are central regulators at the decision point whether a cell survives, or 
dies by apoptosis or necroptosis. In this process, RIPK3 and its substrate 
MLKL are necessary to trigger necroptosis. In contrast to MLKL, however, 
RIPK3 has shown the ability to regulate inflammation independent of 
necroptosis. The relative contribution of necroptosis in cancer disease and 
how IAPs and RIPKs contribute in vivo to this is not well defined yet. 
Therefore, we aimed to understand the role of IAPs and RIPK in the 
pathology of cancer by using transplantable mouse tumor models, and how 
the ability of RIPKs to regulate inflammation in the tumor microenvironment 
alters tumor growth and progression. 
My work contributed to understand how antagonizing the IAPs by Smac-
mimetic compounds in combination with inhibition of p38 mitogen-activated 
protein kinase (MAPK) or MAPK-activated protein kinase MK2 enhanced 
autonomous leukemia cell killing. In more detail, simultaneous inhibition of 
p38 or MK2 in combination with Smac-mimetics significantly increased TNF 
production by leukemic cells mediated by ERK and JNK, which in turn 
resulted in enhanced TNF-induced autocrine cell killing by apoptosis. My 
work also showed that the loss of RIPK3 in the tumor microenvironment 
General Summary 
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decreased the ability of tumor cells to disseminate to the lung. In this 
process, RIPK3 in endothelial cells was responsible to promote tumor cell 
extravasation, which was surprisingly independent of MLKL-dependent 
necroptosis. Rather it was the case that in the absence of cell death, RIPK3 
promoted extravasation by promoting tumor cell- and VEGF-induced 
vascular permeability, which was likely through altering vascular signaling via 
p38/HSP27 and ERK in endothelial cells. Therefore, my work provides a 
novel example, in which RIPK3 functions are of relevance in vivo independent 
of cell death. 
In summary, the work in this manuscript assesses the differential roles of 
IAPs and RIPKs in the tumor and the tumor microenvironment, and to which 
degree necroptosis and RIPK3 alternative functions contribute to the 
outcome of cancer disease. Thereby, the role of IAPs and RIPKs is put in 
context to the literature and potential mechanism underlying the cell death 
independent functions of RIPK3 in endothelial cells are discussed. Further, 
by addressing the benefits and limitations, targeting the necroptosis 
machinery as a strategy for therapeutic intervention in cancer diseases is put 
in perspective. 
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V. Zusammenfassung 
Im Vergleich zur Apoptose ist die Programmierte Necrose oder auch 
Necroptose genannt ein Caspasen-unabhängiger Prozess, bei welchem 
entzündliche Cytokine und 'Danger-associated molecular patterns' (DAMPs) 
sekretiert werden sobald die Zelle als Folge der Necroptose geplatzt ist. 
Programmierer Zelltod ist ein wichtiger Bestandteil während der Entwicklung 
und Homeostase. In Krebszellen sind diese Zelltod Prozesse oft gestört, 
welches fördernd auf Überlebensprogramme und die Zellteilung wirkt, aber 
auch wesentlich zur Chemoresistenz von Krebszellen beiträgt. 
Hierbei spielen die 'Inhibitor of Apoptosis' Proteine (IAPs) und die 'Receptor-
interacting Protein Kinasen'  (RIPKs) eine zentrale Rolle, ob eine Zelle 
überlebt und proliferiert, oder durch Apoptose oder Necroptose stirbt. Dabei 
ist RIPK3 und MLKL, welches ein Substrat von RIPK3 darstellt, unablässig 
zur Ausführung von Necroptose. Im Gegensatz zu MLKL hat sich gezeigt 
dass RIPK3 Entzündungsreaktionen regulieren kann und dies unabhängig 
von der Necroptose Funktion. Der relative Beitrag von Necroptose zum 
Krankheitsverlauf in Krebs in vivo ist bis dato nur wenig verstanden. Deshalb 
war es unser Ziel die Rolle der IAPs und RIPKs im Tumor, sowie der 
Tumorumgebung anhand von Transplantierbaren Maus Tumormodellen, zu 
untersuchen. 
 
Die Resultate meiner Arbeit haben gezeigt, dass die Antagonisierung von 
IAPs mit Hilfe von 'Smac-mimetics' in Kombination mit Inhibitoren gegen p38 
oder MK2 Mitogen-aktivierter Protein Kinasen (MAPKs) die Krebszellen 
effizienter durch Apoptose Induktion getötet wurden. Dabei hat die 
Kombinationsbehandlung von Krebszellen mit Smac-mimetics und p38 oder 
MK2 Inhibitoren dazu geführt dass via ERK und JNK vermehrt autokrines 
TNF produziert wurde im Vergleich zur Einzelbehandlung, welches wiederum 
zur Folge hatte dass Krebszellen vermehrt durch autokrines TNF-induzierte 
Apoptose gestorben sind. Weiters hat meine Arbeit gezeigt dass der Verlust 
von RIPK3 in der Tumor Umgebung dazu geführt hat dass Tumorzellen sich 
Zusammenfassung 
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weniger verbreiten konnten um Ableger zu bilden. Dabei hat sich 
herausgestellt, dass RIPK3 in Endothelzellen dafür verantwortlich war. 
Hierbei unterstütze RIPK3 in Endothelzellen die Induzierung von vaskulärer 
Permeabilität durch Tumorzellen, wie auch durch den Angiogenese Faktor 
'vascular endothelial growth factor' VEGF, welches für die Extravasierung 
von Tumorzellen nötig ist. Überraschend war, dass diese Prozesse 
unabhängig von MLKL-abhängiger Nekroptose war. Wir konnten diesen 
Effekt von RIPK3 darauf zurückführen dass RIPK3 die intrazellulären 
Signalwege via p38/HSP27 und ERK in Endothelzellen gestört hat. Deshalb 
ist diese Arbeit ein Beispiel für eine neue Funktion von RIPK3 welche 
unabhängig von der Zelltod-Funktion ist und so den Krankheitsverlauf von 
Krebs signifikant beeinflussen kann. 
Zusammenfassend thematisiert diese Arbeit die Verschiedenen Funktionen 
der IAPs and RIPKs im Tumor und der Tumorumbegung, und zu welchem 
Grad Necroptose und RIPK3 die weitere Tumorprogression beeinflusst. 
Dabei wurden die Rolle der IAPs und RIPKs in den Kontext zur bekannten 
Literatur gesetzt und die möglichen Mechanismen, welche der Zelltod 
unabhängigen Funktion von RIPK3 in Endothelzellen unterliegen, diskutiert. 
Weiters wurde die Möglichkeit zur therapeutischen Nutzung durch gezielte 
Manipulierung von Necroptose in Perspektive gesetzt. 
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1. Introduction 
1.1. The inhibitor of apoptosis protein (IAP) family 
The inhibition of apoptosis is an important strategy for viruses to promote 
propagation or for cancer cells for survival. The inhibitor of apoptosis 
proteins (IAPs) were first discovered in baculovirus and were found to be 
shared in all metazoan organisms. There are eight IAP proteins found in 
humans (Figure 1) that include the neuronal apoptosis inhibitory protein NAIP 
(encoded by birc1), cellular IAP1 (cIAP1; encoded by birc2), cellular IAP2 
(cIAP2 or BIRC3, X chromosome linked IAP (XIAP or BIRC4), Survivin 
(BIRC5), ubiquitin-conjugating BIR domain enzyme apollon (BIRC6), 
melanoma IAP (ML-IAP or BIRC7), and IAP-like protein 2 (ILP2 or BIRC8)1,2. 
The baculovirus IAP repeat (BIR) domain is shared within all members of the 
IAP family and IAP proteins contain one to three BIR domains. The 
mammalian IAPs are cIAP1, cIAP2 and XIAP and each protein contains three 
BIR domains for protein interaction, an Ubiquitin-associated domain (UBA) 
that mediates binding to poly-ubiquitin (poly-Ub) chains and a really 
interesting new gene (RING) domain that has E3 ubiquitin ligase activity. 
Furthermore, cIAP1 and cIAP2 but not XIAP have a caspase recruitment 
domain (CARD) that was shown to inhibit its E3 ligase activity3-5. Among the 
three IAPs, the cIAPs can bind caspases, but only XIAP can bind and inhibit 
caspase activity. XIAP binds to caspase-9 via the BIR3 domain and prevents 
formation of caspase-9 homodimerization and therefore blocks its activation 
for apoptosis execution6-13. The second mitochondria-derived activator of 
caspases (Smac) is encoded by the DIABLO gene and can inhibit XIAP by 
binding to the same pocket where caspases bind and therefore Smac is 
considered as a pro-apoptotic gene1,2.  
Introduction 
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Figure 1: Structure and function of the mammalian inhibitor of apoptosis proteins 
(IAPs) (adapted from Bai et al, 2014)3-5. 
1.2. The receptor interacting Ser/Thr protein kinase (RIPK) 
family 
The roles of the receptor-interacting protein (RIP) kinase (RIPK) family 
members are important modulators of cell death and inflammation6-13. The 
RIPK are known as serine/threonine kinases and consists of seven members 
(RIPK1-7). As illustrated (Figure 2), the kinase domain (KD) is relatively 
conserved throughout the seven RIP kinases while other functional domains 
are partially shared or unique. Among the gene family, only Ripk1 and Ripk3 
contain a RIP homotypic interaction motif (RHIM) and the RHIM domain is 
necessary for protein-protein interaction to promote necroptosis. While 
RIPK1 contains a death domain (DD) at the C-term, RIPK3 does not obtain 
similarity in the C-terminus with any other known protein. Both, RIPK1 and 
RIPK3 have a prominent function in cell death signaling upon death receptor 
stimulation (e.g. TNFR1, Fas/CD95) at the decision point of survival and 
programmed cell death via either apoptosis or necrosis14-19. 
Introduction 
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Figure 2: Structure and function of the RIPK protein family. Kinase domain (KD), 
intermediate domain (ID), death domain (DD),  caspase activation and recruitment 
domain (CARD), RIP homotypic interaction motif (RHIM), ankryn repeat (ANK) domain, 
leucine rich repeat kinase (LRRK, protein kinase C-associated kinase, RIP-like-
interacting caspase-like apoptosis-regulatory protein kinase and RIP-like-interacting 
caspase-like apoptosis-regulatory protein kinase (RICK) (adapted from Zhang et al., 
2010)20. 
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1.3. Regulation of cell death and immune responses by IAPs 
and RIPK 
Any form of autonomous cell killing that is determined in a genetically 
regulated manner is termed "programmed cell death" (PCD). PCD fulfills 
fundamental functions in both metazoan and plants, and under physiological 
conditions PCD is necessary during development and tissue homeostasis but 
serves also important functions as part of the immune system. An overview 
of different forms of cell death is illustrated in Table 1. 
 
Table 1: Different forms of cell death. 
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1.3.1. Regulation of programmed cell death: apoptosis and necroptosis  
 
Figure 3: Differences between apoptosis and necroptosis (adapted from Ashida et al., 
2011)21. 
 
1.3.2. Mechanisms of apoptosis execution 
Apoptosis is the best described and understood form of PCD22-25. The 
process of apoptosis is defined by clear morphological aspects that include 
the rounding-up of the cell, retraction of pseudopods, decrease in cellular 
volume (pyknosis), chromatin condensation, nuclear fragmentation 
(karyorrhexis), plasma membrane blebbing and engulfment by phagocytic 
cells in vivo26. Apoptosis can be induced by a variety of stimuli, however they 
lead to the activation of initiator caspases, which induces signaling. A 
distinction is made into two main pathways, the extrinsic pathway that is 
Caspase-8 dependent and the intrinsic pathway, which is caspase-9 
dependent. First, the extrinsic pathway can be induced by different 
extracellular stimuli activating death receptors (DRs), which are members of 
the TNF receptor (TNFR) superfamily such as TNFR1, CD95/Fas and TNF-
related apoptosis-inducing ligand receptor-1 (TRAIL). Stimulation of these 
DRs cause procaspase-8 monomers to be recruited to the cytoplasmic 
Introduction 
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region of the DR leading to a complex formation which includes FAS-
associated death domain (FADD), which in turn causes subsequent Caspase-
8 dimerization.  The intrinsic pathway is initiated upon factors released from 
the mitochondria which can occur upon DNA damage, cytoskeletal 
disruption, hypoxia and hormones during development27,28. Here, caspase-9 
mediates downstream apoptosis signaling upon forming a dimer with the 
adapter protein apoptotic protease-activating factor-1 (APAF1)29. Both 
Caspase-8 (extrinsic) and caspase-9 (intrinsic) lead to downstream activation 
of the executioner caspases-3, -6 and -7 which are responsible to execute 
apoptosis by cleaving substrates such as Actin or Lamin, but also activate 
nucleases to cut the DNA between histones30. Activated executioner 
caspases can cleave themselves as well as other executioner caspases, that 
in fact leads to a positive feedback loop, which finally results in the execution 
of apoptosis31. In living animals, apoptotic cells are recognized by find me 
signals such as low levels of ATP or UTP, fractalkine, 
lysophosphatidylcholine, or sphingosine 1-phosphate and subsequent 
cognate receptor signaling mediates internalization of the dying cell by 
resident phagocytes such as macrophages. The phagocytic uptake of 
apoptotic cells is important to prevent secondary necrosis in order to remain 
healthy tissue homeostasis without promoting an inflammatory response26. 
1.3.3. Mechanisms of programmed necrosis or necroptosis 
Necrosis is characterized by swelling of the cell and their organelles, and a 
loss of plasma membrane integrity which subsequently leads to membrane 
rupture and the leak of cellular content into the extracellular space (Figure 3). 
In the past, necrosis was described as a form of cell death that occurs 
accidentally. However, it became clear that necrosis can also be a genetically 
regulated process, and that programmed necrosis or necroptosis is clearly 
distinguishable from apoptosis as it is caspase-independent (Figure 3). It was 
observed in 1988 that TNF can also promote non-apoptotic cell death via 
necrosis in particular cell lines, however the mechanisms behind were still 
elusive for another decade32. It is now known that a variety of stimuli can 
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promote necroptosis such as TNF ligand family members (e.g. TNF, FasL), 
interferons (IFNs), or toll-like receptor 3 (TLR3) 9,10,33-37. Initially it was found 
that Fas ligand induced necrosis and that this was blocked by the loss of 
receptor-interacting protein kinase-1 (RIPK1) function9,10,33. In addition, 
triggering of necroptosis has been described for TLR3 stimulation to occur 
independent of RIPK1 via the adaptor protein TRIF or by infection with 
mouse cytomegaloviruses (MCMV) via the IFN-induced protein DAI38-40. 
Furthermore, it has been identified that the function of RIPK3 and MLKL are 
essential to trigger necroptosis downstream of these different necroptotic 
stimuli whether they depend on RIPK1 or not11-13.  
TNF receptor stimulation is known to trigger RIPK1 recruitment, however the 
role of RIPK1 has been shown to be more complex and it has now been 
recognized that RIPK1 is important but not essential for cytokine induced 
NF-κB activation for survival 41 or cell death by either apoptosis or 
necroptosis42-44. Usually, necroptosis is triggered by RIPK1 interaction with 
RIPK3, RIPK3 dimerization, autophosphorylation of RIPK3 and subsequent 
phosphorylation of mixed lineage kinase domain-like protein (MLKL)45-48. 
Upon phosphorylation, MLKL forms a trimer that leads to the formation of a 
pore-complex that can compromise cell membrane integrity and lead to 
membrane permeability48,49 Therefore, MLKL is currently considered as being 
the essential protein for the execution of necroptosis. More recent studies 
have also suggested additional roles for RIPK1 and RIPK3 in inflammation 
under pathological conditions 39,47,50-52. 
Taken together, necroptosis is considered as an alternative form of PCD to 
apoptosis that is independent of caspases, and which is usually promoted 
when the function of caspases is compromised.  
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1.4. The role of IAPs and RIPKs in the regulation of TNFR1 
mediated signaling 
The role of TNF has been implicated to have pleiotropic functions in a variety 
of processes during immunity, cell death and inflammation. TNF can bind to 
TNF receptor 1 (TNFR1) as well as TNFR2, which can result in contradictory 
outcomes. TNFR1 can signal survival and cell death, while TNFR2 also 
signals survival and is generally not implicated in cell death signaling. The 
outcome upon TNFR1 activation depends strongly on the posttranslational 
modification of the key components in the complex.  
 
Figure 4: The role of RIPK1 and cIAP1/2 at the decision point of TNFR1 mediated 
survival, apoptosis or necroptosis (from Brenner et al., 2015). 
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1.4.1. TNFR1 mediated survival signaling 
TNFR1 is a transmembrane receptor that consists of an extracellular 
cysteine-rich domain, which allows binding of TNF, and the cytoplasmic 
region, which owns a ‘death domain’, serves as a binding site for the adaptor 
protein TNFR1-associated death domain (TRADD). Once TRADD has bound, 
RIPK1 is recruited to the complex followed by the assembly of TRAF2 to 
TRADD, and TRAF2 can then bind cIAP1 and cIAP2. This receptor bound 
complex of TNF-TNFR1-TRADD-TRAF2-cIAP1/2 is termed as complex I and 
all the components central regulators of NF-κB signaling for survival17. The 
type and timing of ubiquitylation of RIPK1 is central for regulating the 
outcome of the cell. The process of ubiquitylation of a protein involves three 
steps that includes the E1 ubiquitin-activating, the E2 ubiquitin-conjugating 
and the E3 ubiquitin-ligating enzymes, which then attach ubiquitin-chains to 
a target protein. Depending on the length and the type of ubiquitin linkage 
attached to a protein, it can be either directed for proteasomal degradation 
(e.g. K11 or K48-linkage) or reinforce stabilization by preferentially K63-
ubiquitin chains attached on a target protein but it also serves as a signaling 
platform by which other proteins can bind to form a complex53,54 (Figure 4). 
In the process of TNFR1 signaling and the formation of complex I, cIAPs 
have E3 ubiquitin-ligase activity that can mediate the attachment of K63-
linked ubiquitin chains to RIPK1, while CYLD has been shown to 
deubiquitylate K63 and M1-linked polyubiquitin. K63-linked chains attached 
to RIPK1 mediate the recruitment of TAK1 kinase complex that consists of 
TAK1, TAB2 and TAB3, which subsequently activates IKK complex. 
Activated IKK then allows for the degradation of IκBα that in turn releases 
p50/p65 which allows for nuclear translocation of p50/p65 promoting survival 
via transcription of canonical NF-κB target genes55-57. 
1.4.2. TNFR1 mediated apoptosis signaling 
In order to switch from a pro-survival phenotype to the cell death phenotype, 
the deubiquitinase cylindromatosis (CYLD) is responsible to remove K63 
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chains from RIPK1 in complex I. Thus, CYLD mediates RIPK1 dissociation 
from the membrane bound complex I in which the formation of the DISC 
complex or complex II9,58. The core components of the DISC complex are 
known to be Fas-associated protein with death domain (FADD), TRADD, 
RIPK3, Caspase-8 and FLIP. The complex II promotes apoptosis mediated 
Caspase-8 activation of downstream caspases, and in parallel complex II 
inhibits necroptosis by cleavage of RIPK1, RIPK3 and CYLD 16,59,60. 
1.4.3. TNFR1 mediated necroptosis signaling 
When complex II triggers cell death, this leads to apoptosis. However under 
conditions where the activity of Caspase-8 is compromised or absent, RIPK1 
can bind RIPK3 (Figure 5). When RIPK1 interacts with RIPK3 under these 
conditions, subsequent RIPK1/RIPK3 and RIPK3/RIPK3 dimerization and 
autophosphorylation of RIPK3 occurs which forms the necrosome61. RIPK3 
then directly phosphorylates MLKL which then results in the execution of 
necroptosis45,46,48,49. Recent evidence suggest that MLKL triggers necroptosis 
by directly forming pore-complexes consisting of trimers in the plasma-
membrane, and thereby triggering the loss of membrane integrity as the final 
step of necroptosis48,49. 
In contrast to the membrane bound complex I, another complex called 
complex IIb can be formed when the function of cIAP1 and cIAP2 is lost. This 
leaves RIPK1 not being ubiquitylated by cIAPs, which in turn leads to 
assembly of RIPK1 with RIPK3, pro-caspase-8, FADD and FLIP-long isoform 
(FLIPL) in the cytosol. Both complex IIa and complex IIb trigger apoptosis via 
activation of Caspase-8. However, FLIPL within complex IIb (also called 
ripoptosome) regulate whether complex IIb signals towards apoptosis rather 
than necroptosis. The form of cell death can be shifted toward necroptosis 
when levels of FLIPL are increased or the apoptotic machinery is 
compromised or inhibited upon formation of complex IIb58,62-64.  
Taken together, the example of TNFR1 stimulation mediated survival via NF- 
κB, or programmed cell death by either apoptosis or necroptosis reveals that 
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the induction of necroptosis is a separate pathway, in which RIPK1, RIPK3 
and MLKL have essential roles. 
 
 
Figure 5: TNF-induced necroptosis requires non-ubiquitylated RIPK1 and Caspase-8 
inactivation. 
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1.5. Characteristics of cancer disease 
Cancer is defined as a disease in which abnormal cells divide without control 
and can invade nearby tissues, in which cancer cells can spread to other 
parts in the human body throughout the blood and lymph system. Cancers 
can be divided into five different categories by means of their tissue of origin. 
The tumor tissue that has originally developed from normal tissue can arise 
from many specialized cell types throughout the body. However, the majority 
of tumors in humans arise from epithelial tissues – the carcinomas. They 
represent the most common human cancers that cause more than 80% of 
cancer-related deaths in the Western world. 
Several lines of evidence support that the formation of a tumor 
(tumorigenesis) is a process that requires multiple steps, in which normal 
human cells acquire genetic alterations that drive the progressive 
transformation into highly malignant cells65. Therefore, Weinberg and 
Hanahan postulated the six hallmarks of cancers in order to provide a 
comprehensive scheme that allows understanding the heterogeneity and 
complexity of the disease by characterization of their common features. 
These steps include 1) sustaining proliferative signaling, 2) evading growth 
suppressors, 3) resisting cell death, 4) enabling replicative immortality, 5) 
Inducing angiogenesis and 6) Activation of invasion and metastasis. In the 
search of the cause of cancer, physical (e.g. UV, x-ray), chemical agents 
(carcinogens) and infectious sources (e.g. EBV, HPV) were identified. 
1.5.1. Hallmarks of Cancer 
Cancer research has illuminated the remarkable heterogeneity of neoplastic 
diseases and the mechanisms how normal cells acquire malignant behavior 
showed to be as complex and diverse. In order to understand and explain 
the complexity of cancer, Weinberg and Hanahan65  wanted to provide an 
organizing principle that puts the different cancer diseases into a logical 
framework. Therefore they proposed six hallmarks of cancer suggesting the 
multistep development of human tumors. Neoplastic cells have acquired 
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distinctive and complementary capabilities in an evolving process that 
transforms normal cells to become tumorigenic and ultimately malignant. 
1.5.2. Resistance to cell death 
Cancer cells develop strategies to avoid signals that induce apoptosis in 
order to enhance their ability to survive and proliferate. In the course of 
cancer development as well as cancer treatment, tumor cells often show 
disrupted apoptotic machinery. For example, most cells that have a 
disrupted cell cycle due to oncogenic mutations will be eliminated by 
apoptosis66,67. Here, the protein TP53 or also termed as p53 plays a central 
role and inactivation of p53 allows for sporadic cancer formation, revealing 
p53 as a tumor suppressor. P53 is a sensor for a variety of stress signals 
such as DNA damage, replicative stress or hyperproliferative signals (e.g. Ras 
signaling) and is considered as the guardian of the genome, thereby critically 
controlling the induction of cell death68. Moreover, different strategies by 
which cancer cells acquire capabilities to circumvent apoptosis induction 
include the upregulation of anti-apoptotic genes (e.g. FLIP, IAPs, Bcl-2 or 
Bcl-xL ) and mutation of pro-apoptotic genes (e.g. Bax, Fas, FADD or 
caspases). 
1.5.2.1. The role of RIPKs in cancer  
Necroptosis in cancer disease has recently emerged that the loss of 
necroptosis in the tumor cells associates with resistance and poor 
prognosis12,69,70. The loss of RIPK3 due to e.g. epigenetic silencing prevented 
MLKL activation and execution of necroptosis71,72. In CLL leukemia cells for 
example, RIPK3 and CYLD downregulation resulted in compromised 
necroptosis execution upon TNF and zVAD (caspase inhibitor)73. Validation of 
primary tumor samples showed high frequency of decreased RIPK3 
expression at mRNA and protein level in colon carcinoma, AML and small-
cell carcinoma70,74,75. The downregulation was often mediated by epigenetic 
silencing, due to hypermethylation of the RIPK3 promoter region 71,75. 
Interestingly, it was observed in these examples that RIPK3 protein and 
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mRNA levels were significantly decreased, while RIPK1 levels remained 
unaffected70,74. 
Interestingly, neither RIPK1 or RIPK3 nor caspases were required for cell 
death upon traditional chemotherapeutic agents such as Doxorubicin, 
Etoposide, Oxaliplatin or 5-fluorouracil (5-FU)70. Such drugs induced cell 
death in epithelial cancer cell lines (HT29 and Colo205) and in lymphoma cell 
lines (Jurkat, H9, U937, BJAB) through non-caspase protease mediated cell 
death via cathepsins70.  
In summary, this suggests that cancer cells can compromise their 
necroptotic and mediate resistance to classical necroptosis inducing stimuli 
(TNF+zVAD+Smac-mimetics, FasL+zVAD, poly(I:C)+zVAD), but necroptosis 
deficiency did not affect the ability of clinically used chemotherapeutics such 
as the DNA damaging agents to kill tumor cells. However, necroptosis is a 
backup mechanism to apoptosis that is thought as a promising strategy for 
therapeutic intervention to overcome apoptosis resistance76. 
1.5.2.2. The role of inhibitor of apoptosis proteins in cancer 
Mutations in the IAP genes have been found throughout different cancers 
that include hepatocellular carcinoma, cervical cancer, liver cancer, 
glioblastoma, medulloblastoma, non-small-cell lung cancer (NSCLC), 
esophageal cancer and pancreatic cancer77-82. The cellular IAPs are 
considered as proto-oncogenes due to common genetic aberrations in 
cancers. Several genetic alterations have been found such as the 11q21-q23 
amplification or the t(11;18)(q21;q21) translocation that fuses the BIR 
domains of MALT1 with that of cIAP2 leading to constitutive activation of NF-
κB83,84. Due to such genetic aberrations, IAP proteins show increase in their 
mRNA or protein levels, or the loss of the endogenous inhibitor Smac in 
many cancers. Among the three IAPs, cIAP2 proved to accurately predict 
overall survival in AML patients, but in childhood de novo AML, increased 
XIAP levels showed to correlate with poor prognosis85-87. 
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1.5.2.3. Mechanisms of IAP inhibition by Smac-mimetic compounds 
IAPs play an important role in cancer survival as they are often upregulated 
and/or altered, or expression of endogenous inhibitor second mitochondrial 
activator of caspases (Smac) is lost. Here, IAPs promote survival (via NF-κB) 
and are often found over-expressed in cancers. For this purpose, efforts 
were put to target the IAP proteins and a variety of inhibitory compounds 
against IAP family members have been generated by targeting different 
domains within the protein. Among several different targeting strategies, 
most attention has fallen on the small-molecule IAP antagonists and 
antisense oligonucleotides as indicated by the fact that several IAP 
antagonizing compounds are currently in clinical- and preclinical trials (e.g. 
MV1 and BV6 from Genentech; Comp A from TetraLogic Pharmaceuticals; 
LBW242 from Novartis;), while two have made it into the clinics (AT-406 from 
Ascenta Therapeutics/University of Michigan and TL32711 from Tetralogic 
Pharmaceuticals)88-91. 
Smac-mimetic compounds are antagonistic small-molecule inhibitors of IAPs 
(IAP antagonists) that mimic the endogenous inhibitor of IAPs Smac. The 
majority of Smac-mimetics target XIAP, cIAP1 and cIAP2 in parallel, which 
can be explained by their homology (Figure 1). IAP antagonists prevent 
caspases and Smac to bind to cIAP1, cIAP2 and XIAP. Here, XIAP is the only 
member that directly binds to Caspase-3/7/9, and which is blocked in the 
presence of IAP antagonists. Smac-mimetics binding to cIAPs in contrast, 
the mechanism turned out more complicated. As illustrated (Figure 6), Smac-
mimetics bind to the BIR3 domain of cIAP1 or cIAP2 and induce a 
conformational change that enhances dimerization of cIAPs via the RING 
domain, which in turn results in an increased E3 ligase activity. cIAPs then 
auto-ubiquitylate, which in turn promotes their degradation via the 
proteasome.88,92,93 
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Figure 6: Smac mimetic compound work as IAP antagonists and lead to cIAP depletion 
via proteasomal degradation (adapted from Fulda 2012)94. 
 
1.5.2.4. The role of necroptosis immunogenic cell death and cancer 
  immunity 
Apoptotic cells are phagocytized by macrophages via eat-me signals usually 
before secondary necrosis occurs42,95-98 that could potentially cause an 
inflammatory response. The term 'immunogenic' cell death refers to the 
consequence of an induction of expression of MHCII, CD40, CD80, and 
CD86 on DCs and the simultaneous release of inflammatory cytokines IL-1β, 
IL-6, IL-12 and TNF when a cell dies. However, in contrast to normal 
apoptosis, a form of immunogenic apoptosis is described in cancer cells 
treated with anthracycline chemotherapies and involves: 1) translocation of 
intracellular Calreticulin, and other endoplasmic reticulum proteins to cell 
surface; 2) secretion of ATP during the blebbing phase of apoptosis; and 3) 
release of the chromatin-binding protein high-mobility group box 1 
(HMGB1)99-103. Interestingly, by binding of HMGB1 to T-cell immunoglobulin 
and mucin-domain containing (TIM)-3, DC activation within tumors can be 
suppressed, although this impacts tumor growth independently of a T cell 
response.  Thus, enhancing immunogenic apoptosis in cancerous cells can 
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be very advantageous in a therapeutic setting because DAMPs induce a host 
anti-tumor immune response. 
More recent studies have tested the immunogenicity of necroptosis in NIH 
3T3 fibroblasts and CT26 cells and evaluated its potential as an alternative 
approach in cancer therapy. In order to cause cancer cells to undergo 
necroptosis, a system to induce dimerization of RIPK and/or FADD in cancer 
cells was used104-107. Necroptotic cancer cells released DAMPs (ATP and 
HMGB1), induce maturation of DCs and production of IFN-g by T cells and 
were therefore able to elicit DC activation and effective cross-priming of 
cytotoxic CD8+ T cells in vivo and in vitro, and mediated anti-tumor 
immunity. 104,105,107-109 
1.5.3. Induction of angiogenesis 
Every cell requires nutrients and oxygen as well as the ability to evacuate 
metabolic wastes and carbon dioxide. Therefore, tumor cells acquire the 
ability to induce angiogenesis and neovascularization of hypoxic tumor tissue 
in order to grow. Angiogenesis and vasculogenesis in adults are mainly 
quiescent, with the exception of the wound healing process or the female 
reproductive cycling. In growing tumors, however, the angiogenic switch 
remains on, causing permanent sprouting of new blood vessels in order to 
support and maintain expanding neoplastic growth110. 
The most prominent regulators of angiogenesis that act with opposing 
effects are vascular endothelial growth factor-A (VEGF-A) and 
thrombospondin-1 (TSP-1). The ligands decoded from the VEGF-A gene that 
signal via tyrosine kinase receptors (VEGFR1-3) are well known in 
orchestrating new blood vessel growth during embryonic and postnatal 
development as well as during homeostatic survival of endothelial cells. 
Moreover, the fibroblast growth factor (FGF) gene family is also well known to 
be involved in wound healing and is also implicated as a proangiogenic 
signal during tumor angiogenesis. In contrast, TSP-1 is a counteracting 
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protein to the VEGF-A induced angiogenic switch by binding transmembrane 
receptors and therefore elevating suppressive signals. 
1.5.4. Activating invasion and metastasis 
The loss or decrease of extracellular matrix (ECM) integrity and with it the 
alteration in cell shape adhesive behavior with neighboring cells is typically 
obtained in carcinomas which coincides with increased invasiveness and 
progressing of a tumor to a more malignant state. E-cadherin is known to be 
critical key suppressor of this process by remaining the assembly of epithelial 
sheets and sustain quiescence of the cells within a tissue111. The process of 
invasion and metastasis has been characterized by series of steps that 
includes cell biologic changes with increasing local invasion of cancer cells, 
followed by intravasation into nearby blood and lymphatic vessels, travel 
through the lumen and by transmigrating through endothelial cells, the cell 
escapes into the parenchyma (extravasation). At distant tissue sites, small 
tumor nodules can be formed (micrometastases) that usually further grow 
into a macroscopic tumor nodule (colonization). 
1.5.4.1. The invasion-metastasis cascade 
Metastasis is a multistep cell-biological process that is characterized by the 
spread of malignant cells to distant organs. This is a result of an evolutionary 
process that is driven by genetic and/or epigenetic alteration within tumor 
cells, which includes the modulation of adjacent stromal cells or even distant 
pre-metastatic non-neoplastic cells. To overcome the different hurdles for a 
tumor cell from the primary tumor to the metastatic site and establish 
macroscopic metastasis, the completion of several steps was accomplished 
that is termed the invasion-metastatic cascade (Figure 7). During this 
process, carcinoma cells deviate from their primary growth site (local 
invasion, intravasation), disseminate systemically via circulation through the 
lymphatic or vascular system (survival, arrest at distant site, extravasation), 
and adapt to survive and establish a microenvironment (micrometastasis 
formation, metastatic colonization). 
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Figure 7: Stromal Cells are altered to aid during the Invasion-Metastasis Cascade (S. 
Valastyan and R.A. Weinberg, 2011). 
1.5.4.2. The role of myeloid during invasion and metastasis 
Among the immune cells, only macrophages, neutrophils and platelets were 
shown to aid in the processes of malignant cell invasion and metastasis, 
while leukocytes have not been reported to be of importance. Macrophages 
or their monocyte precursor cells have been demonstrated as regulators at 
all stages of the metastatic disease by aiding tumor cells for local invasion, 
intravasation to the blood- or lymphatic vessels, escape of the lumen and 
extravasation to peripheral tissues. Microscopy studies of metastatic lungs 
showed that tumor cells directly contact macrophages during extravasation 
and depletion of macrophages resulted in dramatic reduction of the number 
of cancer cells that migrated out of the blood vessels. The recruitment of 
monocytes to sites of extravasation or intravasation was shown to occur in a 
CCL2/CCR dependent manner. Thus, tumor associated macrophages are 
recognized to enhance tumor angiogenesis, promote tumor growth and 
enhance tumor cell migration and invasion112-114 
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Moreover, clinical studies propose that increased numbers of circulating 
neutrophils are correlative of poor prognosis, which has been shown in lung 
and gastric cancers115-117. Mechanistically, neutrophils are considered pro-
metastatic by increasing ability of cancer cells to extravasate via adhesion of 
neutrophils via ICAM-1 on cancer cells118,119. Another specific feature of 
neutrophils is the formation of neutrophil extracellular traps (NETs). A study 
using syngeneic tumor mouse model has indicated that circulating tumor 
cells were trapped within NETs that surprisingly lead to an increase in 
micrometastasis formation by promoting tumor cell adhesion at distant sites 
120. However, formation of metastases is a rare event considering the millions 
of cells entering into the blood stream only very few tumor cells are able to 
form micrometastasis, which makes it difficult to assess experimentally in 
vivo. Therefore, the way myeloid cells aid in the process of metastasis is 
thought to be diverse and mechanism are still not fully understood.  
Initially discovered about a decade ago, it has been discovered that 
(VEGFR1)-expressing bone-marrow derived cells, mainly derived from the 
myeloid lineage, home to distant tissue sites before malignant cells derived 
from a primary tumor colonize this pre-metastatic niche (PMN) to form a new 
metastasis121. The formation of PMNs is a result of the crosstalk between 
factors released from a primary tumor and the microenvironment of a 
secondary organ. In the process, besides tumor released factors such as 
cytokines, chemokines, growth factors and extracellular matrix remodeling 
enzymes, exosomes have been recognized as being critical for the formation 
of the pre-metastatic niche (PMN). Exosomes are small membrane vesicles 
(30-100nm) derived from the luminal membranes of multivesicular bodies that 
are released by cell membrane fusion. Exosomes showed the ability to 
facilitate local and systemic communication between cells via exosomal 
transfer of proteins, mRNAs and microRNAs. Exosomes can directly 
reprogram bone marrow-derived to home to a pre-metastatic spot122-129. 
Here, a pro-inflammatory milieu is created that promotes for additional 
recruitment of myeloid cells into the tumor (mainly macrophage/monocytes 
and neutrophils), and consequently enhancement of vascular permeability as 
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well as re-education of stromal cells. All these processes aid to create a 
successful PMN and consequentially metastasis. 
1.5.4.3. The role of vascular endothelial cells during invasion and 
  metastasis 
The vascular endothelium is structurally different depending on the organ. In 
theory, the vasculature consists of a continuous and non-fenestrated 
endothelial monolayer in the skin, lung heart and brain. The extravasation of 
leukocytes in lung and liver endothelium occurs in the microvasculature, 
while in lymphoid organs this occurs at the higher endothelial venules In 
contrast, leukocytes that extravasate into skin, muscle and mesentery do that 
via the postcapillary venules130,131. This variability therefore leads to functional 
differences in homeostasis, permeability and leukocyte trafficking. 
The microvasculature created by tumor cells and the absence of broad 
pericyte coverage is indicated to promote intravasation. Moreover, the 
capability to enhance breast carcinoma intravasation by the remodeling 
enzymes MMP-1 and MMP-2 and growth factor epiregulin was strongly 
connected to their ability to promote permeability of tumor vasculature132. To 
the latter, the stimulation of vascular permeability is not only of importance 
for intravasation, but is considered as a prerequisite for a cancer cell to 
extravasate. However, in comparison to leukocyte trafficking that is well 
understood, the mechanisms described for tumor cell transmigration vary. 
The process of rolling, adhesion and transmigration (diapedesis) are at least 
partially shared between leukocytes and tumor cells, because malignant cells 
mimic leucocyte migration to a certain degree, but the molecular 
mechanisms remain different133. The most striking difference is that 
leukocytes can alter the endothelium only temporary in contrast to tumor 
cells that induces irreversible changes of structure and function of 
microvasculature. 
The currently reported evidence of tumor cell transmigration suggests 
different strategies. Malignant cells were shown to cross without destroying 
the endothelial monolayer similar to the processes of leucocytes 
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transmigration that includes upregulation of adhesion molecule receptors 
(e.g. LFA-1, L-selectin) on endothelial cells, VEGF-dependent Src-mediated 
loosening of VE-cadherin/β-catenin junctions and subsequent increase of 
vascular permeability134,135, re-organization of the cytoskeleton via myosin-
light chain (MLC) dependent contraction of actin-cytoskeleton136, or the 
induction of programmed cell death. For the latter, it was demonstrated that 
tumor cells were able to induce both apoptosis137 as well as programmed 
necrosis138 of endothelial cells in order to transmigrate through the created 
gap. 
1.5.5. The tumor microenvironment 
The tumor is not just a mass of malignant cells, but consists of many other 
untransformed cells that were recruited (Figure 8). A growing and progressing 
tumor is a dynamic interplay between cancer cells that communicate and 
manipulate the neighboring stromal cells as well as cells of the immune 
system to create an environment that benefits tumor growth. Interestingly, 
the dynamic processes within a tumor that is created by a variety of cellular 
interactions has many parallels to the wound-healing process139,140. This 
communication is mediated by a complex and dynamic network of cytokines, 
chemokines, growth factors, and inflammatory and matrix remodeling 
enzymes. These interactions between malignant and the variety of non-
transformed cells make the tumor microenvironment (TME)141. 
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Figure 8: Cells of the tumor microenvironment (TME). Apart from cancer cells and cancer 
stem cells, the TME of most human tumors consist of stromal cells such as fibroblasts and 
endothelial cells from both, vascular and lymphatic vessels. Both the stromal and 
parenchymal cells of tumors contain distinct cell types and subtypes that promote tumor 
growth and progression. In addition, specific subtypes of inflammatory immune cells such as 
tumor-associated macrophages (TAMs), tumor-associated neutrophil (TAN) granulocytes, 
dendritic cells, B cells and T cells are found as well in most tumors. Important to note, these 
inflammatory immune subtypes can have tumor promoting as well as tumor killing 
capabilities. Each of these special cell types fulfills a special role by applying specific 
functional repertoires to create the TME in its entirety, by which these non-transformed cells 
within a tumor contribute to particular hallmarks (Adapted from Hanahan and Coussens 
2012). 
 
1.5.5.1. The role of inflammatory myeloid cells in the tumor  
  microenvironment 
During the last decade it became clear that inflammation is an important 
component in tumorigenesis. It is recognized that immune cell infiltration is 
fostering certain hallmarks of cancer and It is now accepted that 
inflammatory TME is essential for most tumors to develop and progress. 
Furthermore, chronic inflammation is seen to be associated as a major factor 
of many environmental caused cancers, such as that induced by chronic 
infection.  
Cells of the myeloid lineage make the majority of non-transformed cells in the 
TME. Depending on the subtype of innate immune cell, tumor promoting as 
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well as anti-tumor functions have been described in literature. Tumor-
associated macrophages (TAMs) have been characterized as mainly tumor-
promoting, and high densities of cells expressing macrophage-associated 
markers are generally associated with a poor clinical outcome142. 
Macrophage expression of TNF and IL-6 induces survival signaling in 
neoplastic tissue and resistance to chemotherapy. Further, macrophages can 
enhance angiogenesis by producing factors such as VEGF143,144 and by 
enhancement of VEGF-A bioavailability through enhanced matrix 
metalloproteinase (MMP)-9 activity145,146. 
1.5.5.2. Tumor associated neutrophils 
Neutrophils can neutralize pathogens through phagocytosis and intracellular 
destruction, production of granules containing antimicrobial peptides and 
proteases, and the formation of neutrophil extracellular traps (NETosis) to 
deplete large pathogens. Moreover, by producing cytokines, chemokines and 
ECM remodeling factors neutrophils are also known to be important for their 
role in orchestrating the innate and adaptive immune responses that take 
place both during wound healing and infection. Substantial evidence 
describes neutrophils that are recruited to the tumor to have mainly tumor 
promoting ability by elevating tumor angiogenesis (MMP9, VEGF-A/VEGFR), 
promoting EMT/invasion via CXCL5 or enhance tumor development by 
producing TNF in the TME. In contrast, neutrophils have also been reported 
to interfere with T cell activation depending on the type of cancer, TANs have 
conflicting effects. TAN recruitment was either beneficial or disadvantageous 
for tumor growth, because of differences in TAN subpopulations and their 
capabilities to directly suppress CD8+ T cell proliferation147.  
1.5.5.3. The role of dendritic cells 
Among the cells of the innate immune system dendritic cells (DCs) form a 
central cellular network that shapes adaptive immune responses according 
to peripheral signals. Over the past decade it has been demonstrated that 
tissue DCs consist of developmentally separable subsets with distinct roles 
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in immunity. When compared to monocyte-derived DCs (moDCs) and 
plasmacytoid DCs (pDCs), classical DCs (cDCs) are particularly suited to 
regulating T lymphocyte function98. cDCs can be further divided into two 
subpopulations according to the expression of the transcription factor 
interferon regulatory factor 4 (IRF4) and IRF842. Irf4-dependent cDCs show 
enhanced MHCII antigen presentation and represents the majority of cDCs 
throughout the body and are heterogeneous population that preferentially 
activates CD4+ T cells. In comparison, Irf8-dependent cDC display enhanced 
capability to cross-present soluble and cell-associated exogenous antigen on 
MHCI and preferentially activate CD8+ T cells. The central role of DCs is to 
induce the T cell response that is the foundation of the "cancer-immunity 
cycle" outlined in Chen and Mellman148. This requires the uptake of tumor 
debris/antigens, maturation of the DC (marked by upregulation of co-
stimulatory molecules and inflammatory cytokines), and migration to the 
draining lymph nodes where T cell priming and activation is initiated149,150. 
Both DCs and macrophages within tumors readily uptake cell debris within 
tumors but only the rare IRF8-dependent CD103+ DC population transports 
tumor antigen and activates T cells within the lymph nodes104,151. In addition 
to delivering tumor antigen, only the CD103+ cDC have been found to 
activate naive CD8+ T cells ex vivo following separation of the various cDC 
subsets104. Consistent with these findings, these migratory CD103+ DCs are 
required for rejection of highly immunogenic cancer lines and for 
responsiveness to checkpoint blockade therapy with antibodies against 
programmed death 1 (PD-1)104,106.  
1.5.5.4. The role of cytotoxic T lymphocytes 
The role of T lymphocytes – The T lymphocyte mediated immunity is the 
pivotal element of adaptive immune system. T cells cannot only recognize 
foreign infectious agents such as viral-, bacteria- or parasitic infections, but 
can also detect abnormal malignant cells. Cytotoxic CD8+ T cells and CD4+ 
T helper (Th1) provide the type I immune responses against pathogenic 
sources, and so it is for anti cancer immunity. After initiation of strong type I 
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immune responses, a variety of T cell-inhibitory functions are activated. 
Tumor infiltration of CD8+ T cells occurs in many human cancers. In order to 
allow for antitumor immunity in most model systems the CD8+ T cells occur 
to be crucial. It has been convincingly demonstrated that the cross-
presenting CD8/CD103+ cDC population is required for rejection of highly 
immunogenic cancer lines and for non-responsiveness to checkpoint 
blockade therapy using antibodies against programmed death 1 (PD-1)104,106. 
T cell activation is also modulated by the co-stimulatory signals present in 
the TME. As mentioned earlier in this section, myeloid cells contribute with 
co-stimulatory signals for an effective induction of T cell immunity. However, 
the effectiveness of T cell mediated tumor killing is a result of the competing 
contribution between immune suppressive- and stimulatory signals in the 
TME. Therefore, the CD8 T cells represent the most abundant T cell subtype 
among leucocytes found in many tumors. This results in T-cell mediated 
cytotoxicity against cancer cells, and indeed high densities of CD8+ T cell 
influx into the tumor correlates with a good prognosis. However, depending 
on the polarization phenotype and the abundance of CD4+ T regulatory  
(Treg) cells, the suppressive signals from Tregs such as IL-10, TGF-b and 
CTLA4 overrule T cell stimulatory signals, and thus allow for tumor growth 
and progression. 
1.5.5.5. The role of vascular endothelial cells 
The sprouting of new blood vessel is induced by angiogenic factors such as 
VEGFs, FGFs, PDGFs and chemokines present in the TME, which are mainly 
produced by cancer associated fibroblasts (CAFs), malignant cells and 
myeloid cells. The tumor-associated blood vessels reveal chaotic structure 
and show leakiness that increases interstitial pressure and alters nutrient and 
drug delivery in the TME. Therefore, a tumor requires enhanced angiogenesis 
to fulfill its need for nutrients and oxygenation152.  
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1.5.5.6. The role of IAPs and RIPKs in endothelial cells 
Genetic deletion of Caspase-8 or FADD results in embryonic lethality. The 
embryos die during development around E10.5 stage and show heart 
defects. Embryonic lethality of Fadd-/- or Caspase-8-/- mice was rescued by 
simultaneous genetic loss of Ripk3153,154. Similar to the loss of Caspase-8 and 
FADD, Birc2-/-;Birc3-/- (cIAP1/cIAP2 knockout) mice also obtained heart failure 
when embryos died at around E10.5155. In addition, tissue specific FADD 
depletion or Caspase-8 depletion in Tie2cre mice, where Tie2 is mainly 
expressed by endothelial cells and to a small extent in 
monocyte/macrophage populations, led to embryonic lethality that could be 
rescued with simultaneous RIPK3 deletion156-158  156,157. Therefore, this 
suggests a role for RIPKs and IAPs in regulating cell death by apoptosis and 
necroptosis during embryonic development. 
1.5.5.7. Mechanism of VEGF-induced angiogenesis and vascular 
permeability 
For tumor progression, quiescent endothelial cells and their associated 
pericytes need to undergo the angiogenic switch in order for a tumor to 
vascularize. Many of soluble factors are present in the TME that enforce 
neovascularization and. Among the variety of factors secreted by tumor cells 
or myeloid cells such as PDGFs, HGFs, GM-CSF, chemokines (SDF-1, 
CCL2/MCP-1, RANTES) and pro-inflammatory cytokines (TNF, IL-1β, IL-6). 
For transmigration of immune cells, vascular permeability can be a result of 
either the release of vasoactive signals into the blood or by direct contact of 
lymphocytes with endothelial cells via adhesive junctions159 such as 
intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion 
molecule 1 (VCAM-1). CCL2 ligand signaling through CCR2 receptors on 
endothelial cells has been implicated to promote vascular permeability and 
therefore allow for increased metastatic potential114,160. However, the majority 
of processes that regulate angiogenesis and vascular permeability in disease 
converge through the VEGF signaling axis. The mechanism and signaling 
Introduction 
 39 
events by which VEGF modulates vascular dynamics are illustrated (Figure 
9).  
 
Figure 9: Regulation of vascular permeability by the VEGF- and FGF signaling cascade 
(adapted from Hoeben et al.,  2004; Dudek et al.,  2001; Eichmann et al., 2012; Simons et al., 
2016)161-164. 
1.5.5.8. VEGFR2 signaling  
The Src family of proteins in endothelial cells belongs to the cytoplasmic 
tyrosine kinases that are activated upon phosphorylation of murine VEGFR2 
at tyrosine 949. These Src- dependent signals for permeability go in 
conjunction with alterations in cell shape by modulating the cytoskeleton and 
focal adhesion. Src regulates focal adhesion by phosphorylating focal 
adhesion kinase (FAK). Src/FAK interacts and regulates the turnover of 
integrins in large complexes formed at sites of focal adhesions by which the 
actin cytoskeleton is connected with the extracellular matrix (ECM). 
Upon binding of VEGF, phosphorylation of VEGFR2 at Tyr1173 (Y1175 in 
humans) leads to the activation of PLCγ, followed by generation of inositol 
1,4,5-triphosphate (IP3). IP3 then mediates the release of Ca2+ form the 
endoplasmic reticulum (ER) that leads to the activation of Ca2+-dependent 
protein kinase C (PKC), which then results in signaling through RAF1-MEK-
ERK1/2 cascade165-168. The PLCγ-PKC signaling cascade regulates 
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proliferation, migration and cell fate during development by regulating 
transcription factors of the E26 transformation-specific (ETS) family. These 
factors play a pivotal role in regulating endothelial cell function169-173. In 
addition, Ca2+ signaling is important for activation of nuclear factor of 
activated T cell (NFAT) family of transcription factors. Here, Calmodulin (Ca2+ 
sensor) and Calcineurin that is a Ca2+ dependent Ser/Thr phosphatase 
regulate the nuclear translocation of NFAT which then results in an increased 
signaling by VEGFR2 because of NFAT induced reduction of VEGFR1 
transcription levels 174. 
VEGFR2 leads to the activation of the canonical survival pathway via Src and 
PI3K/AKT, that which results in loosening of tight junction molecules (e.g. VE-
cadherin, ZO-1 Occludin). In addition, VEGFR2 activates PI3K and 
subsequently protein kinase B (PKB or Akt) indirectly, which can also occur 
by activated VE-cadherin or AXL175,176. Akt has a broad spectrum of 
substrates and regulates survival, proliferation and apoptosis177,178 of 
endothelial cells, and is of importance during pathological angiogenesis, 
vascular maturation and metabolism by the mTOR complex 2. Activation of 
eNOS by Akt results in production and diffusion of nitric oxide (NO) from 
endothelial cells to adjacent smooth muscle cells. The activation of NO-
signaling in smooth muscle cells leads to the dilation of the blood vessel. 
In addition to the signaling cascades listed, VEGF stimulation via VEGFR2 
activated also stress kinases such as STAT and p38 MAPK. The activation of 
p38 in endothelial cells has been linked to cell migration and 
lipopolysaccharide (LPS)-induced p38 activation was shown to cause 
vascular permeability179-183. The mechanism by which p38 mediates this is still 
unclear, however the functional role of p38 upon VEGF stimulation is linked 
to HSP27, a known substrate of p38 that inhibits actin polymerization 
tremendously, once activated. Furthermore, the induction of p38 showed to 
depend on neuropilin-1 (NRP1) and Ca2+ influx, but not on PLCγ. Under this 
condition, Src together with RAFTC/Pyk2 was also shown to act on p38 
activation when Ca2+ was released184,185. In summary, the role of other 
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signaling pathways activated by VEGFR2 such as p38 MAPK, SHB, STAT3 
still remains poorly understood. 
1.5.5.9. Crosstalk of FGFR2 and VEGFR2 signaling events  
The fibroblast growth factor (FGF) family interacts with FGF receptors 
(FGFRs) to activate different signaling cascades as illustrated (Figure 9). The 
role of FGFs during development, regulation of angiogenesis and wound 
healing has been well described in literature186. The FGFRs are 
phylogenetically close to VEGFRs and platelet-derived growth factor 
receptors (PDGFRs) and it is therefore not unexpected that there exists 
crosstalk and synergies e.g between FGF and VEGF signaling187. 
Interestingly, FGF-induced angiogenesis and lymphangiogenesis has not 
been permitted upon VEGF inhibition and FGF stimulation of endothelial cells 
resulted in VEGF-A production and release 188-190. FGF signaling through such 
as PI3K-AKT and MEK-ERK are dependent on the adaptor protein FRS2α. 
FGF2 induced FRS2α-dependent activation of ERK1/2 amongst other things 
promoted transcriptional activation of the Vegfr2 gene, which resulted in 
increased sensitivity towards VEGF170. In this sense, FRS2α can also bind to 
VEGFRs and has been shown to be important for angiogenesis, 
arteriogenesis and lymphangiogenesis by activating VEGFA and VEGFC 
signal transduction191. 
1.5.6. Transplantable mouse tumor models 
The use of transplantable syngeneic cell lines into inbred strains have been 
used for a long time and proven to uncover many features of cancer disease, 
such as the intrinsic immunogenicity of dying tumor cells, the existence of 
shared and tumor-specific antigens, and therapeutic intervention could 
provide predictive value192-196. 
The cell lines are derived from spontaneously or carcinogen-induced 
occurring tumors in inbred mouse strains and are then selected for efficient 
propagation both in vitro and in vivo. A range of cell lines have been 
generated that cover a variety of tumor types, such as B16 melanoma, CT26 
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orMC-38 colon carcinoma, Lewis Lung Carcinoma (LLC), 4T1 breast 
carcinoma, and methylcholanthrene-induced fibrosarcoma cell lines. 
These cells are grown in tissue culture dishes and can be injected into 
syngeneic mice. In order to study tumor growth subcutaneous and orthotopic 
inoculation can be used. In addition, tumor dissemination to distant organs 
such as liver, spleen and lung can be studied by resection of an established 
tumor that may allow to study spontaneous metastasis, while intravenous 
injection can be used as an alternative approach that resembles halfway 
metastasis. The advantage of these transplantable models in comparison to 
transgenic tumor models, are the short time frame (few weeks) that tumors 
can be harvested, as well as the reproducibility of tumor growth. 
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2. Aims and Outline 
Our preliminary data suggested, that RIPK1 and RIPK3 have additional 
functions in orchestrating inflammatory responses by directly regulating 
cytokines that was independent of cell death to occur50. Moreover, evidence 
suggested that RIPK3 is a tumor suppressor because it was found that 
RIPK3 is epigenetically silenced in several cancer cell lines as well as patient 
samples12,69. However, it has not been known what the role of necroptosis 
proteins in the tumor microenvironment is. Due to this, we hypothesized that 
RIPKs can alter inflammation in the tumor microenvironment, and that this 
would affect the ability of a tumor to form and grow. Therefore we aimed to: 
 
• Determine the relevance of IAPs and RIPKs in the tumor and the tumor 
microenvironment 
 
• Understand the function of IAPs and RIPKs in vivo and how they affect 
the malignancy of cancer 
 
• Elucidate in detail how IAPs and RIPKs affect inflammation, and 
whether RIPKs cause necroptosis related inflammation or directly by 
modulating cytokines 
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3. Results I 
3.1. Title: RIPK3 promotes vascular permeability via 
VEGF/p38 axis to allow tumor cell extravasation 
independent of its necroptotic function 
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Figure 10: Loss of RIPK3 in the tumor microenvironment reduces tumor nodules in the 
lung in a tumor model of extravasation. (a) Wildtype (Wt) and Ripk3-/- mice were injected 
subcutaneously with 1x105 B16-F10 tumor cells and tumor size was measured over time 
(pooled data of n=2 experiments n=2; 5-7 mice used per group in each experiment. (b) 
RIPK3 protein levels were elevated in total lung lysates of wildtype mice 12h after injection of 
B16-F10 cells shown by representative immunoblot and corresponding quantification of 
pixel density from 3 mice per timepoint.  Fold change relative to untreated Wt control is 
shown from values normalized to Actin. (c) Tumor nodules were counted 14 days post tail 
vein injection (dpi) of B16-F10 cells (2x105) into Ripk3 littermate control mice ( left panel, n=1 
; 3-4 mice used per group) and (d)  tumor nodules were counted 14  dpi of B16-F10 cells 
(2x105) into Wt and Ripk3-/-  mice (left panel, SEM and pooled data shown of n=3 
experiments ; 3-5 mice used per group in each experiment. Corresponding Size is shown of 
tumor nodules classified macroscopically into large (>1mm), medium (0.5mm-1mm) and 
small (<0.5mm) shown (right panel), and corresponding representative macroscopic pictures 
of the lungs were shown. (e) Tumor nodules were counted 20 dpi of MC-38 cells (3x105) into 
Wt and Ripk3-/- mice (n=1, SEM; 6 mice used per group). Each dot represents a mouse 
except stated otherwise; Statistical analysis by t-test. 
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Figure 11: RIPK1 kinase activity but not RIPK3 kinase activity or MLKL in the tumor-
microenvironment is needed for tumor nodule formation in the lung. Tumor nodules 
were counted 14 dpi of B16-F10 cells into (a) Wt and Ripk1K45A/K45A mice (pooled data of n=2 
experiments; 4-7 mice were used per group in each experiment) and representative pictures 
of lungs are shown ,(b) Wt and Ripk3 K51A/K51A mice (pooled data of n=2 experiments; 5-8 
mice were used per group in each experiment)  and (c) into Ripk1Wt/K45A and Ripk1K45A/K45A 
mice (pooled data of n=4 experiments; 3-4 mice were used per group in each experiment). 
(d) Tumor nodules were counted 14 dpi of B16-F10 cells into Wt, Mlkl-/- and Ripk3 -/- mice 
and representative pictures are shown (data from of n=2 experiments; 2-6 mice were used 
per group in each experiment. (e) Paraffin embedded lung sections from mice injected tail 
vein with B16-F10 at indicated time points were stained for TUNEL (FITC) and DAPI. intestine 
of cIAP1-/- mice injected with TNF was used as a positive control and red arrows indicate 
TUNEL positive cells. Each dot represents a mouse; Statistical analysis by t-test. 
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Figure 12: Loss of RIPK3 in the microenvironment does not alter early immune and 
cytokine response upon B16-F10 injection, and bone marrow reconstitution shows 
RIPK3 in the stromal compartment to be important for tumor formation. (a) B16-F10 
luciferase cells home to the lung in both Wt and Ripk3-/- mice measured by IVIS luminescent 
imaging (representative shown from n=2 experiments, 4-5 mice per group in each 
experiment). (b) Cytokine levels in total lung lysates were measured by multiplex bead assay 
and levels of CCL-2, CXCL-1 and IL-1β are shown (data pooled of n=2 experiments, 4-6 
mice were used per group in each experiment) and (c) corresponding immune cell infiltration 
analysis by flow cytometry shows inflammatory monocytes (SiglecF- Ly6G- Ly6Chi CCR2+) 
and neutrophil granulocyte (SiglecF- CD11b+ Ly6G+) populations. Populations were pre-
gated on singlets, live cells, Ter119- and CD45+ cells. (d) Tumor nodules were counted 14 
dpi of B16-F10 into  CD45.1 recipient mice reconstituted with CD45.2 Wt and CD45.2 Ripk3-
/- bone marrow cells ( data pooled of n=3 experiments, 2-4 mice were used per group) and 
(e) CD45.2 or Ripk3-/- recipient mice reconstituted with CD45.1 or Ripk3-/- bone marrow cells 
(data pooled of n=2 experiments, 2-3 mice were used per group). Each dot represents a 
mouse; Statistical analysis done by one-way ANOVA and Bonferroni post-test. 
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Figure 13: Ripk3 promotes tumor cell transendothelial migration independent of its 
ability to block necroptosis. (a) Boyden chamber transendothelial migration assay using 
B16-F10 cells and primary CD31+ endothelial cells (EC) isolated from lungs of Wt, Ripk3-/- or 
Ripk3K51A/K51A mice.  Primary monocytes were isolated on the day of seeding B16-F10 cells 
and 20 hours later, transwells were fixed, stained, and imaged. Images analysis was blinded 
and tumor cells were counted per field of view. The data is pooled from n=2 experiments; 1-
3 transwell inserts were assayed per group in each experiment and 10-17 fields per view 
were analyzed per transwell insert. Total number of B16-F10 transmigrated cells per 
transwell insert is shown. Each dot represents an insert. Statistical analysis by one-way 
ANOVA and Bonferroni post-test. (b) EC monolayers from Wt, Ripk3-/- and Mlkl-/- mice were 
co-incubated with PKH26 stained B16-F10 (+=3x104; ++=9x104) cells and assayed for cell 
death 8 hours later by flow cytometry (n=3; nd.= not determined). Cells were stained for 
annexin V and propidium iodide (live/dead) to identify early apoptotic cells (annexin V+ Live-
Dead-) and dead cells (Live-Dead+ annexin V+ or Live-Dead+ annexin V-). Statistical analysis 
done by one-way ANOVA and Bonferroni post-test. 
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Figure 14: Ripk3 promotes VEGF-A dependent vascular permeability and sprouting.  (a) 
Levels of angiogenic- and remodeling factors in total lung lysates of were measured by 
multiplex bead assay and levels of VEGF-A, FGF-basic, TWEAK and MMP-9 are shown (data 
pooled of n=2 experiment; SEM; 4-6 mice were used per group; each dot represents a 
mouse). (b) Evans blue blood vessel permeability assay of Wt and Ripk3-/- lungs 20h after 
B16-F10 tumor cell injection i.v. (pooled data of n=2 experiments, 4-5 mice were used per 
group in each experiment; Each dot represents a mouse). (c) Primary lung endothelial 
monolayer on transwell inserts were treated with VEGF-A164 (100ng/ml) for 4 hours and 
dextran-FITC permeability assay was performed. Data shows relative fluorescence unit (RFU) 
of dextran-FITC that passed EC barrier (pooled data of n=5 experiments; SEM; 2-3 transwell 
inserts were used per group in each experiment; Each dot represents a transwell insert).(d) 
Subsequent B16-F10 transendothelial migration assay was performed after dextran-FITC 
permeability assay and 20h after B16-F10 (PKH26+) cells were seeded into inserts, 
transwells were fixed, stained, and imaged. Image analysis was blinded and tumor cells were 
counted per field of view. The data is pooled from n=2 experiments; 2-3 transwell inserts 
were assayed per group in each experiment and 10-17 fields per view were analyzed per 
transwell insert. SEM and total number of B16-F10 transmigrated cells per transwell insert is 
shown . Each dot represents an insert. Statistical analysis by one-way ANOVA and 
Bonferroni post-test. (e) HUVECs were transfected with indicated siRNAs and fibrin-gel 
angiogenesis assay was performed. HUVECs were coated on microcarrier beads and 
cultured in fibrin-gels at indicated conditions and after six days sprout length was 
determined. Representative fluorescnece microscopy images are shown. Data from n=3 
experiments; SEM; statistical analysis by t-test. 
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Figure 15: Ripk3 promotes VEGF-A dependent activation of HSP27 MAP kinase 
signaling axis.  (a+b) SV40 large T immortalized endothelial cells isolated from Wt or Ripk3-/- 
mice were treated with VEGF-A or VEGF-B (10ng/ml) and assayed for signaling by 
immunoblot analysis as indicated. Representative immunoblot is shown of n=3 experiments; 
SEM shown. (c) Tumor cells were injected into mice at indicated timepoints and lungs were  
lysated and assayed by immunoblot analysis for phosphorylated p38, RIPK3 and loading 
control. (d) Proposed model: The data suggests that upon VEGF-A or FGF but not TNF 
stimulation RIPK3 promotes the phosphorylation of HSP27 in endothelial cells. We 
hypothesize that the dampened  activation of the p38/HSP27 axis upon loss of RIPK3 could 
explain the reduced responsiveness towards angiogenic factors such as VEGF-A or FGF-b 
and therefore RIPK3 promotes VEGF-A dependent vascular permeability and angiogenesis. 
Summarizing, our study reveals a physiological example that RIPK3 has and novel separable 
roles besides altering cell death modalities. 
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Supplementary Figures 
 
 
Supplementary Figure 1: (a) RIPK3 protein expression in lung and thymus from Wt, Ripk3+/-, 
Ripk3-/-, Ripk3K51A/K51A mice. (b) Cell death was measured using flow cytometry analysis by 
staining live/dead cells with propidium iodide (PI) and apoptotic cells by (Annexin-V FITC) 
after treatment of endothelial cells of Wt, Ripk3-/- and Ripk3K51A/K51A mice for 24h with 
indicated combinations of TNF (100ng/ml), Smac-mimetic compound A (SM, 500nM) or 
zVAD-FMK (5ug/ml). Quantification of one representative experiment shown (n=3). (c) 
Cleaved caspase 3 activity assay from lung lysates of mice injected with B16-F10 (3-4 mice 
per condition). 
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Supplementary Figure 2: Immune cell infiltration analysis of the lung by flow cytometry 
shows CD11b+ dendritic cells (DC; CD11c+, MHCII+, CD11b+ CD103-), CD103 DC 
(CD11c+, MHCII+, CD11b- CD103+) and L6C- Monocytes/Macrophages (CD11c-, CD11b+, 
Ly6C-) and natural killer (NK; NK1.1+ NKp46+) cells at indicated timepoints after B16F10 
injection. Populations were pre-gated on singlets, live cells, Ter119- , CD45+ , SiglecF-, 
Ly6G-). Data pooled of n=2 experiments except NK cells. Each dot represents a mouse; 
SEM displayed and statistical analysis done by one-way ANOVA and Bonferroni post-test. 
 
Supplementary Figure 3: (a) Protein levels of VEGF-A, FGF basic and MMP-9 were 
measured from supernatants of transwell migration assays 20h after addition of tumor cells 
and or monocytes as indicated. (b) SV40 large T immortalized endothelial cells isolated from 
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Wt or Ripk3-/- mice were treated with TNF (10ng/ml) or FGF-b (10ng/ml) and assayed for 
signaling by immunoblot analysis as indicated. Representative immunoblot is shown of n=3 
experiments.  Statistical analysis by one-way ANOVA and Bonferroni post-test. (c) 
Immunoblot quantification of pixel density normalized to total p38 from VEGF-A164 or FGF-b 
treated endothelial cells. Values shown as relative change to untreated Wt control. SEM 
shown and statistical analysis by one-way ANOVA and Bonferroni post-test. 
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5. Discussion 
Our results show RIPK3 did not alter tumor growth of established tumors.  In 
a metastasis model, changes in cytokine production in Ripk3-/- mice 
compared to wildtype after tumor injection were minimal.  Activation of cell 
death in vivo was not detected and when we assessed the involvement of 
different proteins involved in the necrosome, we found the kinase activity of 
RIPK1 was important in the ability of tumor cells to form lung nodules but not 
MLKL.  Bone marrow chimeras showed the involvement of the stromal but 
not the hematopoietic compartment was critical for the loss of tumor nodules 
in the lung in RIPK3 deficient mice.  Finally, we found the loss of RIPK3 in the 
endothelial compartment in the lung decreased the ability of tumor cells to 
transmigrate due to the inability of the RIPK3 deficient endothelial cells to 
respond to permeability factors. These results suggest the role of the 
necrosome is minimal in tumor cell extravasation and presents a novel role 
for RIPK3 as a signaling platform downstream of angiogenic factors such as 
VEGF and FGF. Therefore, my work reveals an example in which non-cell 
death functions of RIPK3 have a strong impact on the disease outcome, and 
that this was solely mediated by RIPK3 without additional manipulation to 
bring RIPK3 into action such as inhibition of Caspase-8 or cIAPs.  
 
In future studies, it needs to be assessed in pre-clinical models whether the 
deficiency of RIPK3, MLKL or kinase inhibition of RIPK1 provides beneficial 
effects in certain diseases. Most important, because RIPK1 and RIPK3 have 
shown to have necroptosis-independent functions in regulating inflammation 
this adds further complexity that needs to be clarified by which mechanism 
RIPK1 and RIPK3 regulate the inflammatory arm versus the necroptotic 
function and how this affects the disease state. Therefore, remaining issues 
and open questions in order to clarify the role of RIPK1 and RIPK3 are 
pointed out and discussed in detail in this section.  
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5.1. The role of RIPK3 in tumor malignancy 
The loss of ability of tumor cells to undergo necroptosis is associated with 
resistance to traditional chemotherapeutic agents and poor prognosis12,69,70. 
In response to typical necroptotic stimuli, the loss of RIPK3 due to epigenetic 
silencing prevented MLKL activation and execution of necroptosis71,72. 
Insight about the role of RIPK3 in cancer development was confirmed when 
the loss of RIPK3 in myeloid cells accelerated FLT3-internal tandem 
duplication (FLT3-ITD) induced myeloproliferation and the development into a 
leukemia197. Here, RIPK3 promoted the differentiation of leukemia-initiating 
cells (LIC) and identified RIPK3 to regulate inflammasome activation by 
regulating the release of IL-1β. This was also observed when RIPK3 
expression was tested in primary human AML samples and revealed that 
RIPK3 was downregulated. This data identified RIPK3 and the inflammasome 
as key regulators to suppress AML development. Interestingly, the loss of 
MLKL did accelerate leukemogenesis, but it only partially phenocopied the 
loss of RIPK3, which suggest that RIPK3 has additional functions that 
mediate leukemogenesis. Another recent study reported that the depletion of 
RIPK3 in KrasG12D pancreatic ductal epithelial cells (PDEC) enhanced 
proliferation and aggressiveness in vitro due to increased expression of Bcl-
xL and c-Myc, and loss of CDK4. However, this was in contrast to the finding 
that p48cre;KrasG12D;Ripk3-/- mice blocked against pancreatic oncogenesis 
compared to   p48cre;KrasG12D;Ripk3+/+ mice, as well as orthotopic injection of 
KrasG12D;Rip3−/− and KrasG12D;Ripk3+/+ tumor cells into pancreas of wildtype 
mice  showed decreased tumor growth upon loss of RIPK3 (198. The findings 
from Höckendorf et al., suggest RIPK3 as a tumor suppressor, while Seifert 
et al., would suggest the opposite, which in turn suggests that the pancreas 
may have a unique milieu and that the RIPK3 functions are dependent on the 
cellular and inflammatory context. From that we can conclude that RIPK3 
most likely has tumor suppressor function69-72,197, but the role of RIPK3 in 
tumors may depend on the tumor type and the surrounding milieu forming 
the tumor microenvironment. 
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5.2. The role of RIPK3 in the tumor microenvironment 
My work shows an important role for RIPK3 in stromal cells of the TME but 
not in the hematopoietic compartment (Figure 12). In addition upon 
intravenous injection, the loss of RIPK3 in the TME resulted in decreased 
formation of tumor nodules with slightly reduced tumor size, and that this 
was independent of MLKL-dependent necroptosis(Figure 10c+d+e and 
Figure 11d). We then tested whether subcutaneous tumor growth was 
affected in the RIPK3 deficient mice and we found no change in size of B16-
F10 tumors compared to wildtype (Figure 10a), which was supported by the 
same finding of Seifert and colleagues198. Yet, we found that the loss of 
MLKL only slightly reduced pulmonary tumor nodules compared to wildtype 
mice (Figure 11d). In summary, the study from Höckendorf et al., and ours 
provide an example in which the alternative functions of RIPK3 come into 
play without inhibition of cIAPs197.  
Further supportive, we have found that RIPK3 protein levels increased in 
lungs (Figure 9b), which was similar to the observation that RIPK3 levels were 
increased in tumor harboring pancreases198. In addition, orthotopic injection 
of KrasG12D PDEC or Pdx1cre;KrasG12D;TP53R172H cells into wildtype and Ripk3-/-, 
showed smaller tumors upon loss of RIPK3 in the TME198. This could be 
explained by the function of RIPK3 in the TME that caused immune 
suppression, by which RIPK3- and Mincle-dependent expression of CXCL1 
promoted recruitment of highly immunogenic myeloid and T cell infiltrates. 
Indeed, blocking CXCL1 protected against pancreatic adenocarcinoma 
progression. This suggests that RIPK1 and RIPK3 in the TME can 
significantly contribute to tumorigenesis and tumor progression. Further, it is 
unclear what process causes the upregulation of RIPK3 protein levels in 
lungs after B16 injection or in pancreatic tumors and how this affects levels 
of necroptosis in such cells and due to its proinflammatory nature enhances 
immunogenicity. Another alternative that needs to be assessed is, whether 
increased RIPK3 levels are required for cytokine production of CXCL1198 
similar to the observation in Wong et al., 50.  
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5.3. Defining necroptosis in experimental studies 
In order to study RIPK1 and RIPK3 alternative functions it is crucial to detect 
MLKL, which is a substrate of RIPK3 and considered the crucial effector 
molecule in necroptosis. So far, MLKL has not been reported yet to have 
other functions such as the RIPKs, besides its requirement for necroptosis 
execution by forming pores in the membrane once phosphorylated by RIPK3. 
Other downstream substrates that have necroptosis execution capabilities 
are likely to exist but need to be identified. 
In order to detect necroptosis, a monoclonal antibody against human 
phosphorylated MLKL was generated that was suitable for labeling tissue 
sections48 and a monoclonal antibody against phosphorylated mouse MLKL 
was developed but works only to detect by immunoblotting199. Alternatively, 
to conclude for the presence of necroptosis in tissues the absence of 
apoptotic markers and the presence of necrotic lesions in comparison to 
MLKL-/- animals, by which necroptosis is blocked, needs to be assessed. It is 
therefore of great importance to develop robust tools to detect necroptotic 
cells in tissues in order to study the function of necroptosis in vivo.  
5.4. The contribution of necroptosis-independent RIPK3-
mediated inflammation to tumor malignancy 
It is still not entirely clear whether the loss of RIPKs blocked the severity of 
inflammatory disease models or cancer disease due to regulating 
inflammation, or cell death or both. So far, very little is known how RIPK3 or 
RIPK1 control inflammation independent of cell death. In our study, the loss 
of RIPK3, but not the loss of MLKL in the TME decreased the number of 
tumor nodules in lungs of mice injected with B16F10 melanoma or MC-38 
colon carcinoma cells (Figure 10c-e). This suggested necroptosis 
independent function of RIPK3 is important for the tumor formation. Due to 
the ability of RIPKs to drive cytokines we tested whether this is the case in 
our phenotype. Therefore we tested whether cytokine and chemokines levels 
in lungs were altered in a RIPK3 dependent manner, but mostly the levels of 
cytokines have not been altered (Figure 12b, Figure 14a and Supplementary 
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Figure 3a). This is supported in part by the bone marrow chimera 
experiments, in which the loss of RIPK3 in stromal cells showed reduced 
tumor nodules compared to wildtype mice reconstituted with RIPK3 deficient 
bone marrow cells(Figure 12d+e). However, RIPK3 deficient mice that were 
reconstituted with wildtype bone marrow showed a slight increase in tumor 
nodule formation compared to those with RIPK3 deficient bone marrow 
(Figure 12e). This indicates that RIPK3 in myeloid cells may partially be 
contributing to promote tumor nodule formation that could be due to 
regulating the secretion or production of certain inflammatory signals such as 
cytokines in vivo. 
The discrepancy that no major changes were observed when looking at total 
lung lysates may be explained by the fact that cytokines are secreted remain 
different to what a cell has produced/stored within the cell. Another 
explanation may be that the inflammatory signals released from 
macrophages in the process tumor cell extravasation may be disrupted by 
RIPKs and this might be of actual importance for aiding local extravasation of 
tumor cells, but because the amount of tumor cells injected and the majority 
of them dies, inducing extravasation unrelated overwhelming cytokine 
response, may vanish the differences that are of relevance to a single tumor 
cell transmigrating. Therefore, such processes need to be examined at the 
single-cell level by using flow cytometric analysis in combination with 
histopathological analysis to assess cellular compartments and cytokine 
levels. Furthermore, such tumor models that depend on RIPKs need to be 
assessed in necroptosis deficient Mlkl-/- mice. 
5.5. Potential cell death independent complex formation with 
RIPK1 and RIPK3 upon angiogenic signals in endothelial 
cells 
The fact that RIPK1 kinase dead transgenic mice are viable and resistant to 
necroptosis, while NF-κB signaling was not compromised, it has been 
established that RIPK1 kinase-independent scaffolding function is essential 
to inhibit cell death. In addition, if Caspase-8 is inhibited or absent, RIPK1 
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interacts via the RHIM domain with RIPK3 to form RIPK1/RIPK3 complex 
which is followed by as series of phosphorylation events on RIPK1 and 
RIPK3 that leads to the formation of amyloid filamentous structures known as 
the necrosome 200. 
Due to the role of RIPK1 and RIPK3 complex formation during cell death 
signaling such as the necrosome formation200, this would suggest that RIPK1 
and RIPK3 might work in complex to promote tumor formation in the lung 
independent of necroptosis. In addition, we hypothesize that such complexes 
play a role in signaling events that are not related to TNFR1 mediated 
complex formation. Our observation suggested that vascular permeability 
related signaling upon VEGF and FGF-b stimulation (e.g. HSP27, ERK) was 
altered in the RIPK3 deficient endothelial cells (Figure 15a-c, Supplementary 
Figure 3b). We therefore proposed an important role for RIPK3 in endothelial 
cells, in which a non-necroptotic role of RIPK3 alters vascular signaling and 
therefore causing tumor cell induced permeability issues(Figure 14b-d).  
To test whether such complexes exist upon VEGF and FGF stimulation, 
immunoprecipitation experiments need to be performed to test whether 
RIPK1 and RIPK3 are in complex upon angiogenic stimuli similar to those 
formed in TNFR1 mediated signaling. For example, other prominent 
interaction partners of RIPK1 and RIPK3 in TNFR1 cell death signaling such 
as Caspase-8 and FADD or TAK1 in complex with RIPK1 that is known to 
mediate survival signaling. It is also possible that the hypothetical complex is 
consisting of other unknown interaction partners that could be identified by 
mass spectrometry upon immunoprecipitation of RIPK1 or RIPK3. This 
should be performed in cells that lack MLKL or Caspase-8, as well as both in 
order to prove the existence of a complex in the absence of necroptosis- or 
apoptosis function. Such experiments should resolve whether complex 
formation is of importance and if RIPK1 and RIPK3 work in concert during 
necroptosis-independent signaling events upon angiogenic stimuli in 
endothelial cells. 
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5.6. The role of posttranslational regulation by ubiquitylation 
of RIPK3 
The ubiquitylation status of RIPK1 has been shown to determine which 
distinct complexes were formed, which consequently determined whether 
cells survive, or die by either apoptosis or necroptosis. In contrast to what is 
known about RIPK1 ubiquitylation, the role of RIPK3 ubiquitylation and how 
this affects complex formation and signaling is much less defined. For 
example, it has been observed that the severe skin inflammation in A20-/- 
mice52 was rescued upon genetic deletion of RIPK3. A20 is known to have 
deubiquitylating activity and it was reported to remove ubiquitin chains from 
RIPK3 at Lys 5, which in turn prevented the interaction of RIPK1 and RIPK3 
that was necessary for necroptosis induction201. RIPK3 was also shown to be 
ubiquitylated by cIAPs in vitro202. 
We observed that RIPK3 protein levels are increasing at 12h after intravenous 
tumor cell injection in the majority of the lungs that were assessed (Figure 
10b). Increased RIPK3 protein levels were also reported in pancreatic tumors 
and the adjacent non-tumor tissue198. In addition, the levels of p38 activation 
in the lungs of RIPK3 deficient mice remains poorly activated at two- and six 
hours after B16F10 injection compared to wildtype (Figure 15c) or decreased 
activation of HSP27 in RIPK3 deficient endothelial cells after angiogenic 
stimuli (Figure 15a+b, Supplementary Figure 3b). In order to determine 
whether posttranslational modifications and not transcriptional activation are 
involved to elevate RIPK3 protein levels as well as altering signaling events 
(e.g. decreased p38/HSP27), the expression of RIPK3 mRNA needs to be 
assessed. If no correlation between mRNA levels and an increase in protein 
levels is measured, this would strongly suggest that RIPK3 could be 
protected from degradation due to posttranscriptional modifications. The 
ubiquitin system is known to mediate proteosomal degradation as well as 
protein stabilization of a target protein, depending on the type of ubiquitin-
linkage to a certain protein. Here, ubiquitylation of RIPK3 by K63- or linear-
linked ubiquitin chains is known to often mediate non-degradative complex 
formation201,203. Together, this supports the hypothesis that in the case of 
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RIPK1 and RIPK3, posttranscriptional modification such as that mediated by 
K63-linked ubiquitin chain attachment to RIPK3 could be a substantial 
regulator not only during necroptosis but also during non-cell death related 
functions or RIPK3 and RIPK1. 
In order to detect ubiquitylation on a protein, cultured cells can be 
transfected with plasmids encoding for the protein of interest (e.g. RIPK1 and 
RIPK3) and epitope tagged ubiquitin. Immunoprecipitation of RIPK3 will then 
be tested with respective antibodies to detect ubiquitin after immunoblotting. 
Ubiquitylation can also be tested in vitro by incubating my purified protein 
with ubiquitin, ubiquitylation E1 and ubiquitylation E2 and then tested using 
antibodies to detect ubiquitin by immunoblotting204. Another approach to 
detect ubiquitin and ubiquitin attachment sites on the protein of interest 
could be mass-spectrometry based proteomics205,206. Deubiquitylating 
enzymes (DUBs) can be used to identify how an ubiquitin chain on a protein 
is build up. This is achieved due to the specificity of different DUB family 
members to the type of ubiquitin linkage. For example, the DUBs TRABIO 
and DUBA are known to specifically remove K63-linked ubiquitin from a 
protein205,206. Upon incubation of the ubiquitylated protein of interest with 
such different DUBs it can be determined how an ubiquitin chain on a protein 
is build up which then helps to understand where and how a protein is 
ubiquitylated. 
5.7. A potential link between Caspase-8 and RIPK3 in 
regulating endothelial barrier function via the permeability 
and cell motility regulator c-Src 
In contrast to its role in apoptosis signaling, recent discoveries revealed that 
Caspase-8 is involved in a number of alternative processes independent of 
cell death. These findings mainly describe the alternative functions of 
Caspase-8 to have a role in signaling pathways implicated in cell 
proliferation, cell migration and cell adhesion207-212. Interestingly, Caspase-8 
showed to be phosphorylated on Tyr380 by c-Src, which was associated 
with a decreased activity of Caspase-8213 that in parallel enhanced its 
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alternative function to promote cell adhesion, migration and tumor 
progression207,210. The tyrosine kinase Src is known to promote endothelial 
permeability in normal physiological processes as well as in inflammatory 
pathologies214. Src is part of the canonical pathway induced by 
VEGF/VEGFR2 that is responsible for metastasis-associated 
hyperpermeability of endothelial cells215 and represents a major element in 
regulating vascular permeability. In this process, Src mediates activation of 
MLCK/MLC that is responsible for endothelial cell retraction via 
rearrangement of the cytoskeleton, direct phosphorylation of VE-cadherin, as 
well as activation of the focal adhesion kinase FAK that is responsible for 
promoting Calpain/FAK/p42 ERK complex formation where Caspase-8 is 
also participating in the complex 208,214. 
This suggests a link between our observation that RIPK3 promotes vascular 
permeability and the role of Src signaling via Caspase-8. This may provide 
new insight by which RIPK3 promotes vascular permeability (Figure 14b-d) 
by assessing Src-dependent phosphorylation of Caspase-8 in our context, 
because Caspase-8 activity is also known to directly regulate necroptosis-
related complex formation. Vice versa, dominant negative mutant forms of 
Caspase-8 (e.g. T380A) can be used to determine RIPK3 stability and 
complex formation, and how does this affect intracellular signaling of 
endothelial cells upon angiogenic- and permeability factors. It remains to be 
determined whether RIPK3 similar to Caspase-8 would participate in the 
focal adhesion complex (Calpain/FAK/p42 ERK), maybe together with 
Caspase-8 upon VEGF stimulation. Complex formation and protein/protein 
interaction can be tested by immunoprecipitation experiments, and 
fluorescence microscopy to define the localization of RIPK3 to certain 
structures such as tight-junctions, adherens junctions or focal-adhesion 
complexes. 
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5.8. The role of RIPK3 in metabolic processes during 
angiogenic switch 
In the past few years, endothelial cell metabolism showed to be crucial 
regulator of the angiogenic switch152, which in turn allows for vessel sprouting 
by inducing quiescent endothelial cells to become highly active, proliferate 
and migrate in order to form new blood vessels, during normal development 
as well as tumor related blood vessels216. 
Glycolysis has been implicated as a driving force of vessel sprouting, and 
upon VEGF signaling endothelial cells double their glycolytic flux. Due to the 
role of cell metabolism in determining vessel sprouting, and the fact that 
RIPK3 has been associated with metabolic enzymes during necroptosis 
signaling such as GLUL, GLUD1 and PYGL13, this led us hypothesize that the 
loss of RIPK3 may alter endothelial cell metabolism in the presence of 
angiogenic factors independent of necroptosis. Our preliminary results 
indicate that the loss of RIPK3 in normal quiescent endothelial monolayers 
showed a modest decrease in the potential of elevating oxidative 
phosphorylation when stressed with inhibitors of mitochondrial respiratory 
chain (Oligomycin and FCCP), but not in glycolysis (Figure 16a). This 
proposes that loss of RIPK3 decreases the mitochondrial respiration 
potential. Surprisingly, when endothelial monolayers were activated for four 
hours with VEGF-A, we observed a strong dependency on RIPK3 to 
upregulate the oxygen consumption rate (OCR; measurement for 
mitochondrial respiration) (Figure 16b). One explanation for the decrease in 
mitochondrial respiration at basal levels and stressed levels could be that 
RIPK3 deficient endothelial cells own less mitochondria than wildtype cells 
do, but this needs to be analyzed by fluorescence microscopy. Moreover, 
GLUL catalyzes glutamine from glutamate and GLUD1 catalyzes glutamine 
into α-ketoglutarate. This process has been critical in cancer cells as a 
source of nitrogen and carbon216,217, but the relative importance of glutamine 
metabolism in endothelial cells and how this is affected in the process of 
tumor cell extravasation and metastasis needs to be determined216,217.  
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Interestingly, together with our data this suggests a potential role for RIPK3 in 
regulating mitochondrial respiration in endothelial cells during VEGF 
stimulation. But it is not known whether decreased potential in mitochondrial 
respiration has any functional impact on endothelial cells in to context of the 
angiogenic switch152, and whether RIPK3 mediates VEGF-dependent 
changes in mitochondrial respiration are of relevance to cause permeability 
and/or allow for tumor cell transmigration in our study (Figure 13b+ca). 
Therefore, it needs to be further investigated how RIPK3 is related to the 
metabolism and mitochondrial function in the process of necroptosis-
independent function in endothelial cells. 
 
Figure 16: VEGF stimulation induced metabolic changes are reduced in RIPK3 deficient 
endothelial cells. Using the Seahorse technology, Glycolysis is measured by the 
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extracellular acidification rate (ECAR) and mitochondrial function by Oxygen consumption 
rate (OCR). Oligomycin inhibits ATP production by mitochondria, FCCP depolarizes the 
mitochondrial membrane and drives oxygen consumption rate to restore mitochondrial 
potential. Rotenone and antimycin A shut down mitochondrial respiration to allow calculation 
of non-mitochondrial respiration (Image from www.seahorsebio.com). (a) Phenotype stress 
test was performed on endothelial monolayers and (b) the mitochondrial stress test was 
performed on endothelial monolayers in the absence or presence of VEGF for 4h. From this, 
the seahorse technology allows determining basal respiration rate, ATP production, proton 
leak, maximal respiration, spare capacity and non-mitochondrial respiration. 
5.9. Targeting RIPKs in cancer therapy 
Pharmacological inhibitors have been generated in order to block the pro-
inflammatory property of necroptosis. RIPK1 kinase inhibition can be 
achieved by necrostatin-1 (Nec-1) or Nec1s, which is the next generation 
inhibitor with enhanced specificity and less off targets have been recently 
developed. GSK'840, GSK'843 and GSK'872 were found to efficiently inhibit 
RIPK3 kinase activity218 and necrosulfonamide are described to inhibit MLKL 
activity46 to block necroptosis. The fact that Ripk1-/- mice are lethal but the 
kinase dead mutant mice such as RIPK1K45A/ K45A or RIPK1D138N/D138N are viable 
and have no obvious altered phenotype suggests that kinase activity of 
RIPK1 may provide a save target47,219,220.  
RIPK3-/- or RIPK3 kinase dead (K51A) mice used in our study are viable and 
fertile218, while in contrast the mice with inactivated kinase activity via 
mutation of D161N reveals embryonic lethality due to an elevated apoptosis 
of the endothelial cells in the yolk sac, which was dependent on RIPK1 and 
Caspase-8, and it has been suggested by Newton et al., that the kinase 
mutant D161N may alter structural features that lead to enhanced likelihood 
of RIPK3/RIPK1 dimerization and cell death signaling via apoptosis47. Similar 
findings were observed using certain RIPK3 kinase inhibitors that support the 
finding in D161N mice. This suggest that the use of RIPK3 kinase inhibitors 
for therapy need to be evaluated and it needs to be determined in the 
context of tumor type whether such inhibitors would have a beneficial effect 
due to blocking necroptosis or by enhancing apoptosis. Moreover, depletion 
or downregulation of RIPKs and MLKL in cancer has been associated with 
bad outcome due to enhanced resistance to cell death induction and 
contributing to chemotherapeutic resistance. Therefore, inhibition of RIPK1, 
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RIPK3 or MLKL in cancer therapy would not be advantageous69,70,74,75. On the 
other hand, as my work and others show198 that ablation of RIPK1 kinase 
activity or RIPK3 in the TME is able to decrease tumor burden, would make 
them suitable for cancer therapy. But whether the positive effects of RIPK 
inhibition in stromal and immune compartment provides beneficial effects 
over the disadvantageous properties of RIPK or MLKL inhibition in the tumor 
itself, needs to be addressed in detail in specific tumor models. Necroptosis 
induction may provide alternative therapeutic strategy to overcome 
apoptosis-chemoresistance in a subgroup of cancer patients. 
5.10. Therapeutic potential of immunogenic cell death via 
necroptosis 
Recent reports identified necroptotic cancer cells as efficient inducers of an 
adaptive immune response 105,107-109. However, the role of necroptosis in vivo 
and how it contributes to causing an immune response against tumors is still 
poorly understood. Moreover, the mechanism and effector molecules have 
been well described in immunogenic apoptosis with anthracycline 
agents101,221, but are not understood yet in terms of necroptosis. As 
necroptosis was recently reported to occur in lung adenocarcinoma upon 
treatment with Dasatinib and Paclitaxel, it reveals relevance during cancer 
treatment, and similar to immunogenic apoptosis, necroptosis could 
potentially be desired to enhance anti-tumor immunogenicity. Therefore, the 
ability of necroptosis to induce anti-tumor immunity needs to be evaluated in 
detail, as necroptosis of the cells in the TME could also have 
disadvantageous effects198. Despite the latter, further studies need to identify 
chemotherapeutic drug combinations that could enhance necroptosis of 
tumor cells (e.g. Dasatinib and Paclitaxel)222, which in turn could be combined 
with immune checkpoint blockade to unleash anti-tumor immunity. 
Whether similar to immunogenic apoptosis, the immunogenicity of 
necroptotic cells is mediated by the same effector molecules such as 
HMGMB1 or extracellular DNA or other pathways that contribute to DC 
activation, needs to be elucidated25,108. Correlative evidence of DAMPs and 
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cytokine release by necroptotic cells and the activation of DCs indicate 
importance in cancer immunity. However, it is neither determined what the 
contribution of each factor is, nor is it clear what DC related sensory 
pathways usually activated upon immunogenic apoptosis, and were of actual 
importance for necroptosis induced DC maturation. Multiple receptors on 
DCs have been implicated in the induction of cellular immunity during cancer, 
including DAMP recognition by toll-like receptors (TLRs), ATP detection by 
P2RX7, and DNA sensing by cGAS/STING223-226.  
It needs to be evaluated which DAMPs and inflammatory cytokines released 
from necroptotic cancer cells induce DC maturation in vitro and in vivo. 
Cancer cells and DC co-incubation assays can be used to evaluate which 
pathways are important in mediating DC activation by necroptotic cells. After 
co-incubation FACS analysis will be performed to measure DC activation by 
CD80 and CD86. In addition, using the ovalbumin expressing cell lines will 
also evaluate the ability of DCs to activate naïve T cells, as DC maturation by 
necroptotic cells does not necessarily correlate with their ability to cross-
present antigen. 
5.11. Concluding remarks 
Taken together, the findings described are of crucial importance, because 
triggering necroptosis is considered as a promising strategy to overcome 
apoptosis resistance in cancer therapy. Therefore, this implies that such 
treatment options need to be validated in vivo, because it is not known to 
which degree necroptosis inducing agents/drug combinations also hit 
untransformed cells, and therefore any treatment strategy will likely be tumor 
type specific. To the latter, the fact needs to be taken into account that 
decreased RIPK3 levels in the tumor correlated with poor prognosis but the 
loss of RIPKs in the tumor microenvironment can slow down tumor growth, 
this needs to be assessed in distinct tumor models. In addition, treatment 
option would only account for established tumors where the inhibition of 
RIPKs for example would prevent tumor progression, while the goal to 
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prevent cancer development by preventive administration of drugs would 
never be feasible. 
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